American Journal of Otolaryngology - Head and Neck Medicine and Surgery
Volume 28, Issue 4 , Pages 260-266 , July 2007

Botulinum neurotoxins: fundamentals for the facial plastic surgeon

  • Robert Todd Adelson, MD

      Affiliations

    • Corresponding Author InformationDivision of Facial Plastic and Reconstructive Surgery, Department of Otolaryngology, University of Florida, PO Box 100264, Gainesville, FL 32610, USA. Tel.: +1 352 392 4461.

Received 29 July 2006

References 

  1. Munchau A, Bhatia KP. Uses of botulinum toxin injection in medicine today. BMJ. 2000;320:161–165
  2. Zimbler MS, Nassif PS. Adjunctive applications for botulinum toxin in facial aesthetic surgery. Facial Plast Surg Clin North Am. 2003;477–482
  3. Lamanna C. The most poisonous poison. Science. 1969;130:763–772
  4. American Society of Plastic Surgeons—Statistics for 2005. http://www.plasticsurgery.org/public_education/2005Statistics.cfm. Accessed on 6/15/2006.
  5. American Academy of Facial Plastic and Reconstructive Surgery—Statistics for 2005. http://www.aafprs.org/media/stats_polls/m_stats.html. Accessed on 6/15/2006.
  6. Lam SM. The basic science of botulinum toxin. Facial Plast Surg Clin North Am. 2003;11:431–438
  7. Jost WH, Kohl A. Botulinum toxin: evidence-based medicine criteria in rare indications. J Neurol. 2001;248(Suppl):S39–S44
  8. Aoki KR. Botulinum toxin: a successful therapeutic protein. Curr Med Chem. 2004;11(23):3085–3092
  9. Neuenschwander MC, Pribitkin EA, Sataloff RT. Botulinum toxin in otolaryngology: a review of its actions and opportunities for use. Ear Nose Throat J. 2000;79(10):788–801
  10. Wenzel RG. Pharmacology of botulinum neurotoxin serotype A. Am J Health Syst Pharm. 2004;61(Suppl):S5–S10
  11. Scott AB. Development of botulinum toxin therapy. Dermatol Clin. 2004;22:131–133
  12. Erbguth N. Historical aspects of botulinum toxin. Neurology. 1999;53:1850–1853
  13. Van Ermengem EP. Classics in infectious disease: a new anaerobic bacillus and its relation to botulism. Rev Infect Dis. 1979;4:701–719
  14. Gunn RA. Botulism toxin: from van Ermengem to the present. Rev Infect Dis. 1979;1(4):720–721
  15. Thakker MM, Rubin PAD. Pharmacology and clinical applications of botulinum toxins A and B. Int Ophthalmol Clin. 2004;44(3):147–163
  16. Blitzer A, Slica L. Botulinum toxin: basic science and clinical use in otolaryngology. Laryngoscope. 2001;111:218–226
  17. Schantz EJ, Johnson EA. Botulinum toxin: the story of its development for the treatment of human disease. Perspect Biol Med. 1997;40:317–327
  18. Scott AB, Rosenbaum A, Collins C. Pharmacologic weakening of extraocular muscles. Invest Ophthalmol. 1973;12(12):924–927
  19. Scott AB. Botulinum toxin injection into extraocular muscles as an alternative to strabismus surgery. Ophthalmology. 1980;87(10):1044–1049
  20. Tsui JK, Eisen A, Mak E, et al. A pilot study on the use of botulinum toxin in spasmodic torticollis. Can J Neurol Sci. 1985;12(4):314–316
  21. Carruthers A, Carruthers J. History of the cosmetic use of botulinum A exotoxin. Dermatol Surg. 1998;24:1168–1170
  22. Carruthers A, Carruthers J. Cosmetic uses of botulinum A exotoxin. Adv Dermatol. 1997;12:325–347[discussion 348]
  23. Carruthers JD, Carruthers JA. Treatment of glabellar frown lines with C. botulinum-A exotoxin. J Dermatol Surg Oncol. 1992;18(1):17–21
  24. Carrruthers JD, Lowe NJ, Menter A, et al. Double-blind, placebo-controlled study of the safety and efficacy of botulinum toxin type A for patients with glabellar lines. Plast Reconstr Surg. 2003;112:1089–1098
  25. Blitzer A, Binder WJ, Aviv JE, et al. The management of hyperfunctional facial lines with botulinum toxin. Arch Otolaryngol Head Neck Surg. 1997;123:389–392
  26. Keen M, Blitzer A, Aviv J, et al. Botulinum toxin A for hyperkinetic facial lines: results of a double-blind, placebo-controlled study. Plast Reconstr Surg. 1994;94(1):94–99
  27. Rohrich RJ, Janis JE, Faigen S, et al. The cosmetic use of botulinum toxin. Plast Reconstr Surg. 2003;112(Suppl):S177–S187
  28. Matarasso A, Deva AK. Botulinum toxin. Plast Reconstr Surg. 2002;109:1191–1197
  29. Setler PE. Therapeutic use of botulinum toxins: background and history. Clin J Pain. 2002;18:S119–S124
  30. Simpson LL. A comparison of the pharmacological properties of clostridium botulinum type C1 and C2 toxins. J Pharmacol Exp Ther. 1982;223(3):695–701
  31. Simpson LL. The action of botulinal toxin. Rev Infect Dis. 1979;1(4):656–659
  32. Gonnering RS. Pharmacology of botulinum toxin. Int Ophthalmol Clin. 1993;33(4):203–226
  33. Barth H, Roebling R, Fritz M, et al. The binary clostridium botulinum C2 toxin as a protein delivery system. J Biol Chem. 2002;277(7):5074–5081
  34. Richard JF, Petit L, Gibert M, et al. Bacterial toxins modifying the actin cytoskeleton. Int Microbiol. 1999;2(3):185–194
  35. Klein AW. Contraindications and complications with the use of botulinum toxin. Clin Dermatol. 2004;22:66–75
  36. Bajjalieh SM. Synaptic vesicle docking and fusion. Curr Opin Neurobiol. 1999;9:321–328
  37. Coffield JA, Bakry N, Zhang RD, et al. In vitro characterization of botulinum toxin types A, C and D action on human tissues: combined electrophysiologic, pharmacologic and molecular biologic approaches. J Pharmacol Exp Ther. 1997;280(3):1489–1498
  38. Glogau RG. Review of the use of botulinum toxin for hyperhidrosis and cosmetic purposes. Clin J Pain. 2002;18(Suppl):S191–S197
  39. Blasi J, Chapman ER, Link E. Botulinum neurotoxin A selectively cleaves the synaptic protein SNAP25. Nature. 1993;365:160–163
  40. Foran P, Lawrence GW, Shone CC, et al. Botulinum neurotoxin C1 cleaves both syntaxin and SNAP-25 in intact and permeabilized chromaffin cells: correlation with its blockade of catecholamine release. Biochemistry. 1996;35(8):2630–2636
  41. Angaut-Petit D, Molgo J, Comella JX, Faille L, et al. Terminal sprouting in mouse neuromuscular junctions poisoned with botulinum type A toxin: morphological and electrophysiological features. Neuroscience. 1990;37(3):799–808
  42. Pamphlett R. Early terminal and nodal sprouting of motor axons after botulinum toxin. J Neurol Sci. 1989;92(2-3):181–192
  43. Harris CP, Alderson K, Nebeker J, et al. Histologic features of human orbicularis oculi treated with botulinum A toxin. Arch Ophthalmol. 1991;109(3):393–395
  44. Eleopra R, Tugnoli V, Rosetto O, et al. Different time courses of recovery after poisoning with botulinum neurotoxin serotypes A and E in humans. Neurosci Lett. 1998;256:135–138
  45. Eleopra R, Tugnoli V, Quatrale R, et al. Different types of botulinum toxin in humans. Mov Disord. 2004;19(Suppl 8):S53–S59
  46. Mezaki T, Kaji R, Kohara N. Comparison of therapeutic efficacies of type A and F botulinum toxins for blepharospasm: a double-blind, controlled study. Neurology. 1995;45:506–508
  47. Sadick NS, Matarasso SL. Comparison of botulinum toxins A and B in the treatment of facial rhytides. Dermatol Clin. 2004;22:221–226
  48. Sloop RR, Cole BA, Escutin RO. Human response to botulinum toxin injection: type B compared with type A. Neurology. 1997;49(1):189–194
  49. Critchfield J. Considering the immune response to botulinum toxin. Clin J Pain. 2002;18(Suppl):S133–S141
  50. Kessler KR, Skutta M, Benecke R. Long-term treatment of cervical dystonia with botulinum toxin A: efficacy, safety, and antibody frequency. J Neurol. 1999;246(4):265–274
  51. Carruthers A, Carruthers J. Toxins 99, new information about the botulinum neurotoxins. Dermatol Surg. 2000;26:174–176
  52. Pearce LB, Borodic GE, Johnson EA, et al. The median paralysis unit: a more pharmacologically relevant unit of biologic activity for botulinum toxin. Toxicon. 1995;33(2):217–227
  53. Carruthers J, Faigen S, Matarasso SL. Consensus recommendations on the use of botulinum toxin type A in facial aesthetics. Plast Reconstr Surg. 2004;114(Suppl):1S–22S
  54. Yamauchi PS, Lowe NJ. Botulinum toxin types A and B: comparison of efficacy, duration, and dose-ranging studies for the treatment of facial rhytides and hyperhidrosis. Clin Dermatol. 2004;22(1):34–39
  55. Botox Package Insert, Allergan, Inc. www.botox.com/site/professionals/home.asp
  56. Hexsel DM, De Almeida AT, Rutowitsch M, et al. Multicenter, double-blind study of the efficacy of injections with botulinum toxin type A reconstituted up to six consecutive weeks before application. Dermatol Surg. 2003;29(5):523–529
  57. Myobloc Package Inset. Solstice Neurosciences, Inc. http://www.myobloc.com
  58. Baumann L, Black L. Botulinum toxin type B (Myobloc). Dermatol Surg. 2003;29(5):496–500
  59. Flynn TC. Myobloc. Dermatol Clin. 2004;22:207–211
  60. Dysport Package Information, Ipsen Limited; http://www.ipsen.ltd.uk.
  61. Markey AC. Dysport. Dermatol Clin. 2004;22:213–219
  62. Flynn TC, Clark RE. Botulinum toxin type B (MYOBLOC) versus botulinum toxin type A (BOTOX) frontalis study: rate of onset and radius of diffusion. Dermatol Surg. 2003;29(5):519–522
  63. Alam M, Dover JS, Arndt KA. Pain associated with injection of botulinum toxin A exotoxin reconstituted using isotonic sodium chloride with and without preservative. Arch Dermatol. 2002;138:510–514
  64. Van Laborde S, Dover JS, Moore M, et al. Reduction in injection pain with botulinum toxin type B further diluted using saline with preservative: a double-blind, randomized controlled trial. J Am Acad Dermatol. 2003;48(6):875–877
  65. Callaway JE. Botulinum toxin type B (Myobloc): pharmacology and biochemistry. Clin Dermatol. 2004;22:23–28
  66. Hsu TS, Dover JS, Arndt KA. Effect of volume and concentration on the diffusion of botulinum exotoxin A. Arch Dermatol. 2004;140(11):1351–1354
  67. Mantell AM. Dilution, storage and electromyographic guidance in the use of botulinum toxins. Dermatol Clin. 2004;22:135–136
  68. Almeida De Trindade AR, Kadunc BV, Di Chiacchio N, et al. Foam during reconstitution does not affect the potency of botulinum toxin type A. Dermatol Surg. 2003;29(5):530–531
  69. Sarifakioglu N, Sarifakioglu E. Evaluating the effects of ice application on the pain felt during botulinum toxin type-A injections: a prospective, randomized, single-blind controlled trial. Ann Plast Surg. 2004;53(6):543–546
  70. Klein AW, Mantell A. Electromyographic guidance in injecting botulinum toxin. Dermatol Surg. 1998;24:1184–1186
  71. Vartanian AJ, Dayan DH. Complications of botulinum toxin A use in facial rejuvenation. Facial Plast Surg Clin North Am. 2003;11:48–492

PII: S0196-0709(06)00209-2

doi: 10.1016/j.amjoto.2006.09.002

American Journal of Otolaryngology - Head and Neck Medicine and Surgery
Volume 28, Issue 4 , Pages 260-266 , July 2007

Article Tools